• Karyopharm Therapeutics will present selinexor myelofibrosis trial data at the American Society of Hematology meeting on Dec. 12-13, 2026.
• Phase 3 SENTRY findings show ongoing clinical benefit through week 48 with selinexor combined with ruxolitinib; presentation is scheduled for Dec. 13.
• Early Phase 2 SENTRY-2 results support selinexor monotherapy activity in JAK inhibitor-naïve myelofibrosis; findings will be presented Dec. 12.
• A Dec. 12 poster will feature updated Phase 1b/2 STOMP results evaluating selinexor with mezigdomide and dexamethasone in relapsed/refractory multiple myeloma.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611040901PR_NEWS_USPR_____NE88503) on November 04, 2026, and is solely responsible for the information contained therein.